Company intelligence / Profile preview

Stradvise

Seattle, Washington, United Statesstradvise.me ↗

Ownership: Private
Development stage: Other

Overview

StradBio has demonstrated in preclinical models that its split-cytokine technology can activate target immune cells at concentrations 10,000 times lower than non-targeted cells, potentially reducing systemic toxicity. No human clinical results have been published yet.

The company’s approach aims to deliver potent immunotherapies with improved safety by restricting activation to specific cellular contexts.

Platforms are being applied broadly across multiple payloads and targets.

Key leadership includes veterans of Seattle Genetics and Neoleukin Therapeutics.

Therapeutic areas: OncologyImmunology
Modalities: Cytokine mimeticSmall moleculeProtein
Industry: Biotech

Partnerships

None disclosed

Beyond the preview

Go deeper on Stradvise.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stradvise.

Explore the full profile